Alnylam Pharmaceuticals Inc

Alnylam’s Q4 2025 earnings beat forecasts, driven by Onpattro sales, a solid pipeline, and value‑based pricing—yet patent cliffs and rising competition pose risks to future growth.

Alnylam’s Q4 2025 results turn a loss into a $45 M profit, fueled by $1.78 B in product revenue from its first‑in‑class ASO and siRNA therapies, and a 2026 outlook of $3.4‑$3.8 B in growth.

Alnylam’s Amvuttra sales slowdown prompts Bernstein to cut its price target, but the company’s RNAi pipeline and upcoming J.P. Morgan conference may boost investor confidence.

Alnylam hires Vertex veteran Stuart Arbuckle to sharpen regulatory strategy and fast‑track its RNA‑silencing pipeline, boosting market‑launch prospects.

Alnylam boosts siRNA capacity with a $250 M expansion in Massachusetts and gains a new Canadian indication for AMVUTTRA®, poised to cut costs, lift margins, and broaden its therapeutic reach.

Alnylam’s Health Canada approval for AMVUTTRA and Nasdaq‑100 inclusion boost its RNA‑i pipeline and market reach, promising revenue gains amid manufacturing and reimbursement challenges.

Alnylam’s Nasdaq‑100 debut boosts its RNAi drug pipeline and investor visibility, highlighting breakthroughs in liver, eye, and CNS gene‑silencing therapies.

Alnylam’s Nasdaq‑100 debut boosts visibility, liquidity, and investor confidence in its biopharma growth and pipeline.

Alnylam’s Nasdaq 100 debut, $508 price target, and strategic debt buy‑back signal a stronger capital structure poised to accelerate its RNAi pipeline and dominate the growing non‑opioid therapeutics market.

Alnylam’s siRNA strategy blends cutting‑edge RNA tech with value‑based pricing and HTA wins to capture high‑margin markets, from cardiology to Huntington’s disease.